Immunome to Present at the Stifel 2023 Healthcare Conference
10 November 2023 - 2:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced that Clay Siegall, PhD, President and
CEO of Immunome, will present at the Stifel 2023 Healthcare
Conference on Wednesday, November 15, at 3:00 p.m. ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company’s
website at www.immunome.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 90
days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, targeted effectors, radioligand
therapies and ADCs. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231110745339/en/
Investor Contact Corleen Roche Chief Financial Officer
investors@immunome.com
Media Contact Andrew W. Mielach LifeSci Communications
amielach@lifescicomms.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024